Finerenone Recommended for the Treatment of Patients With Heart Failure With LVEF 40% in the EU
January 31, 2026
January 31, 2026
LEVERKUSEN, Germany, Jan. 31 -- Bayer, a pharmaceutical and life sciences company, issued the following news release on Jan. 30, 2026:
* * *
Finerenone recommended for the treatment of patients with heart failure with LVEF 40% in the EU
CHMP adopts positive opinion for the marketing authorization of finerenone for patients with heart failure (HF) with left ventricular ejection fraction (LVEF) 40%, i.e. mildly reduced or preserved LVEF, in the European Union . . .
* * *
Finerenone recommended for the treatment of patients with heart failure with LVEF 40% in the EU
CHMP adopts positive opinion for the marketing authorization of finerenone for patients with heart failure (HF) with left ventricular ejection fraction (LVEF) 40%, i.e. mildly reduced or preserved LVEF, in the European Union . . .